Clinical Trials Browser

Phase 1 × Interventional × MK 2206 × Clear all

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Phase 1 Active not recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

NCT00963547 2024-06-04

MK-2206-015

Phase 1 Terminated

33 enrolled 13 charts

Breast Neoplasms

NCT00848718 2019-11-12

MK-2206-003

Phase 1 Completed

77 enrolled 24 charts

Neoplasms

NCT00670488 2019-04-01

MK-2206-002

Phase 1 Completed

104 enrolled 28 charts

Neoplasms

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1 Terminated

47 enrolled 12 charts

GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT01021748 2018-08-07

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Phase 1 Completed

63 enrolled 17 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

NCT01344031 2018-07-23

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01263145 2017-08-25

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT01783171 2017-08-22

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT01071018 2015-09-07

A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

Phase 1 Completed

Other solid neoplasm

Solid Tumors

NCT01281163 2015-08-27

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT01295632 2015-08-27

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Phase 1 Completed

BreastCNSGynecologic

Breast Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT01245205 2014-10-23

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Phase 1 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT01231919 2014-04-29

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasmSarcoma

Myeloproliferative Syndrome, Transient, Pdgfra-Associated Chronic Eosinophilic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blast Crisis, Burkitt Lymphoma, Leukemia, Hairy Cell, Leukemia, Mast-Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Leukemia, Myelomonocytic, Juvenile, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Phase 1 Completed

17 enrolled 7 charts

Neoplasms

NCT01705340 2013-09-30

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Phase 1 Terminated

BreastGastrointestinal

Breast Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Breast Neoplasms, Male

NCT01147211 2013-05-03

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

Phase 1 Unknown

Carcinoma, Non-Small-Cell Lung